Eli Lilly and Company $LLY Shares Bought by Index Fund Advisors Inc.

Index Fund Advisors Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 159.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,218 shares of the company’s stock after acquiring an additional 749 shares during the quarter. Index Fund Advisors Inc.’s holdings in Eli Lilly and Company were worth $950,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of LLY. PNC Financial Services Group Inc. increased its stake in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. Nuveen LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $4,613,912,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the last quarter. Cohen Investment Advisors LLC increased its stake in shares of Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after acquiring an additional 773,947 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after acquiring an additional 765,010 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jamere Jackson purchased 200 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the stock an “overweight” rating in a report on Thursday. UBS Group decreased their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $948.06.

Eli Lilly and Company Stock Down 2.6%

NYSE LLY opened at $833.08 on Monday. The stock has a market cap of $788.47 billion, a PE ratio of 54.45, a P/E/G ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The business has a 50 day moving average price of $742.42 and a two-hundred day moving average price of $765.55. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.